These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31804741)

  • 21. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
    Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study.
    Zhou X; Zhan T; Xu X; Lan T; Hu H; Zhou Y; Xia D; Wang J; Wang Y; Xiao Y; Li W
    J Dermatolog Treat; 2024 Dec; 35(1):2302071. PubMed ID: 38247364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
    Wang HH; Liu CW; Li YC; Huang YC
    Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical resolution of pemphigus vulgaris on rituximab.
    Cusick E; Silverstein D
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
    Kridin K; Ahmed AR
    Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
    Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
    J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
    Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
    Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
    Saleh MA; Saleh NA
    Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
    Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
    Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
    Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
    J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.
    Aryanian Z; Balighi K; Daneshpazhooh M; Karamshahi E; Hatami P; Goodarzi A; Tajalli M; Vance TM
    Int Immunopharmacol; 2021 Jul; 96():107755. PubMed ID: 34162136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
    Saleh MA
    J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
    El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
    Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.